BRD2 bromodomain (1-455 aa) (His-Tag), human recombinant

BRD2 bromodomain (1-455 aa) (His-Tag), human recombinant is available at Gentaur for Next week delivery.

A protein involved in chromatin targeting

Biomolecule/Target: BRD2

Alternates names: RING3, RNF3, Bromodomain containing 4, D6S113E, FSH, FSRG1, NAT, RING3, RNF3

Synonyms: RING3, RNF3, Bromodomain containing 4, D6S113E, FSH, FSRG1, NAT, RING3, RNF3

Background Information: The acetylation of histone lysine residues plays a crucial role in the epigenetic regulation of gene transcription. A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. These domains function in the linking of protein complexes to acetylated nucleosomes, thereby controlling chromatin structure and gene expression. Thus, bromodomains serve as “readers” of histone acetylation marks regulating the transcription of target promoters. The BET family of proteins, defined by tandem Bromodomains and an Extra Terminal domain, include BRD2, BRD3, BRD4, and BRDT. The BET proteins play a key role in many cellular processes, including inflammatory gene expression, mitosis, and viral/host interactions. The isolated individual or tandem bromodomains of BRD2 and BRD4 have been shown to bind acetylated histone tails, serving to couple histone acetylation marks to the transcriptional regulation of target promoters. Small molecule inhibitors of these interactions hold promise as useful therapeutics for human disease. This protein can be used for the study of bromodomain binding assays, screening inhibitors, and selectivity profiling.

Reconstitution Instructions: N/A

NCBI Gene Symbol: BRD2

Gene ID: 6046

NCBI Accession: P25440